Table 3.
Baseline characteristics of the study 2 sample (n=49)
| Characteristic | Descriptive statistic |
|---|---|
| Sex (% female) | 67.3 |
| Race (%) | |
| White | 61.2 |
| African-American | 26.5 |
| Asian | 6.1 |
| Ethnicity (% non-Hispanic) | 97.9 |
| Age (MN±SD) | 39.7±9.96 |
| CLBP duration (median, in months) | 78.7 |
| Worst pain past 24 hours (mean±SD) | 6.0±2.36 |
| Average pain past 24 hours (mean±SD) | 4.6±2.49 |
| Best pain past 24 hours (mean±SD) | 3.1±2.59 |
| PROMIS pain interference 8a (mean±SD) | 23.7±9.12 |
| Medications (%) | |
| As-needed opioids | 14.3 |
| Antidepressants | 49.0 |
| Neuroleptics | 38.7 |
| As-needed NSAIDs | 42.9 |
| HOME: opioid exposure (mean±SD) | 2.2±1.54 |
| HOME: euphoric response (mean±SD) | 3.2±1.25 |
CLBP, chronic low back pain; HOME, History of Opioid Medical Exposure; NSAID, non-steroidal anti-inflammatory drug; PROMIS, Patient-Reported Outcomes Measurement Information System.